|Articles|April 1, 2001 (Updated: November 15, 2020)

Pharmaceutical Executive

  • Pharmaceutical Executive-04-01-2001
  • Volume 0
  • Issue 0

Regulation: OK After All

Author(s)Kevin Gopal

London-The National Institute of Clinical Excellence (NICE) has decided that Roche's Xenical (orlistat) should be available from the National Health Service for managing obesity and its related problems, but it should not be viewed as a slimming pill.

Articles in this issue

almost 25 years ago

Internet DTC - Minding Your P's & Q's

almost 25 years ago

Regulation: Two-Track Plan

almost 25 years ago

Policy: Tectonic Shift

almost 25 years ago

Liberated?

almost 25 years ago

A Matter of Taste

almost 25 years ago

Partnerships: Bargaining Biotechs

almost 25 years ago

Pediatric Mandate

almost 25 years ago

Genentech's Passion for Patients

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content